{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-355664","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2026-08-18T21:00:14+00:00","discovered_at":"2026-08-18T21:02:03.200792+00:00","generated_at":"2026-08-18T21:02:24.708610+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amgen terminates Crohn's disease collaboration with TScan; effective Nov 10, 2026","bullets":["Amgen gave notice Aug 12, 2026 to terminate Research Collaboration and License Agreement; effective Nov 10, 2026.","No early termination penalty; TScan received $30M upfront in 2023, potential milestones over $500M now unlikely.","Collaboration used TScan's target discovery platform for Crohn's disease; Amgen had exclusive worldwide license.","TScan expects no future milestone/royalty payments unless Amgen continues to exploit product candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-355664","json":"https://secwatch.observer/filing/0001193125-26-355664.json","markdown":"https://secwatch.observer/filing/0001193125-26-355664.md","text":"https://secwatch.observer/filing/0001193125-26-355664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/0001193125-26-355664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/d143845d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-18T21:02:24.708610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}